The DOI matches its Crossref record; 308 of the 308 references it cites were found in a registry or an index.
Considerations for the Design of Antibody-Based Therapeutics
Open accessAbstract
Antibody-based proteins have become an important class of biologic therapeutics, due in large part to the stability, specificity, and adaptability of the antibody framework. Indeed, antibodies not only have the inherent ability to bind both antigens and endogenous immune receptors but also have proven extremely amenable to protein engineering. Thus, several derivatives of the monoclonal antibody format, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, have demonstrated efficacy for treating human disease, particularly in the fields of immunology and oncology. Reviewed here are considerations for the design of antibody-based therapeutics, including immunological context, therapeutic mechanisms, and engineering strategies. First, characteristics of antibodies are introduced, with emphasis on structural domains, functionally important receptors, isotypic and allotypic differences, and modifications such as glycosylation. Then, aspects of therapeutic antibody design are discussed, including identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and design of antibody derivatives based on fragmentation, oligomerization, or conjugation to other functional moieties. Finally, strategies to enhance antibody function through protein engineering are reviewed while highlighting the impact of fundamental biophysical properties on protein developability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Smith, G. P. (1985) · Science · doi:10.1126/science.4001944 · Cited by 4,143
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Zhou, H.-X., Rivas, G., & Minton, A. P. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125817 · Cited by 2,149
Structure and function of immunoglobulins
Schroeder, H. W., & Cavacini, L. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.09.046 · Cited by 1,905
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,382
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Stability of Protein Pharmaceuticals: An Update
Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., & Katayama, D. S. (2010) · Pharmaceutical Research · doi:10.1007/s11095-009-0045-6 · Cited by 1,098
Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding
Nimmerjahn, F., & Ravetch, J. V. (2005) · Science · doi:10.1126/science.1118948 · Cited by 1,037
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange
van der Neut Kolfschoten, M., Schuurman, J., Losen, M., Bleeker, W. K., Martínez-Martínez, P., Vermeulen, E., den Bleker, T. H., Wiegman, L., Vink, T., Aarden, L. A., et al. (2007) · Science · doi:10.1126/science.1144603 · Cited by 975
THE HIGH-AFFINITY I g E RECEPTOR (FcεRI): From Physiology to Pathology
Kinet, J.-P. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.931 · Cited by 968
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Properties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization
Ridgway, J. B. B., Presta, L. G., & Carter, P. (1996) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/9.7.617 · Cited by 810
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R., Davies, A., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E., Sangha, R., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 800
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Diebolder, C. A., Beurskens, F. J., de Jong, R. N., Koning, R. I., Strumane, K., Lindorfer, M. A., Voorhorst, M., Ugurlar, D., Rosati, S., Heck, A. J. R., et al. (2014) · Science · doi:10.1126/science.1248943 · Cited by 796
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 737
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
Krapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674
Enhanced antibody half-life improves in vivo activity
Zalevsky, J., Chamberlain, A. K., Horton, H. M., Karki, S., Leung, I. W. L., Sproule, T. J., Lazar, G. A., Roopenian, D. C., & Desjarlais, J. R. (2010) · Nature Biotechnology · doi:10.1038/nbt.1601 · Cited by 653
The promise and challenge of high-throughput sequencing of the antibody repertoire
Georgiou, G., Ippolito, G. C., Beausang, J., Busse, C. E., Wardemann, H., & Quake, S. R. (2014) · Nature Biotechnology · doi:10.1038/nbt.2782 · Cited by 652
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Effects of glycosylation on the stability of protein pharmaceuticals
Solá, R. J., & Griebenow, K. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21504 · Cited by 646
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Biophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629
Structure-Immunogenicity Relationships of Therapeutic Proteins
Hermeling, S., Crommelin, D. J. A., Schellekens, H., & Jiskoot, W. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000029275.41323.a6 · Cited by 617
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607
Agarwal, P., & Bertozzi, C. R. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5004982 · Cited by 605
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592
Immunogenicity of therapeutic proteins: Influence of aggregation
Ratanji, K. D., Derrick, J. P., Dearman, R. J., & Kimber, I. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2013.821564 · Cited by 589
Kaetzel, C. S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00278.x · Cited by 582
Kontermann, R. E., & Brinkmann, U. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.02.008 · Cited by 578
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., Jonas, M., Anderson, M. E., Setter, J. R., & Senter, P. D. (2015) · Nature Biotechnology · doi:10.1038/nbt.3212 · Cited by 557
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Immunogenicity of Therapeutic Protein Aggregates
Moussa, E. M., Panchal, J. P., Moorthy, B. S., Blum, J. S., Joubert, M. K., Narhi, L. O., & Topp, E. M. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.002 · Cited by 529
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
An efficient route to human bispecific IgG
Merchant, A. M., Zhu, Z., Yuan, J. Q., Goddard, A., Adams, C. W., Presta, L. G., & Carter, P. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-677 · Cited by 510
Liu, H., & May, K. (2012) · mAbs · doi:10.4161/mabs.4.1.18347 · Cited by 484
Schaefer, W., Regula, J. T., Bähner, M., Schanzer, J., Croasdale, R., Dürr, H., Gassner, C., Georges, G., Kettenberger, H., Imhof-Jung, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019002108 · Cited by 482
Fc‐fusion proteins: new developments and future perspectives
Czajkowsky, D. M., Hu, J., Shao, Z., & Pleass, R. J. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201379 · Cited by 476
IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G
von Pawel-Rammingen, U. (2002) · The EMBO Journal · doi:10.1093/emboj/21.7.1607 · Cited by 473
Jain, N., Smith, S. W., Ghone, S., & Tomczuk, B. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1657-7 · Cited by 459
Therapeutic protein aggregation: mechanisms, design, and control
Roberts, C. J. (2014) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.05.005 · Cited by 455
Chen, K., Xu, W., Wilson, M., He, B., Miller, N. W., Bengtén, E., Edholm, E.-S., Santini, P. A., Rath, P., Chiu, A., et al. (2009) · Nature Immunology · doi:10.1038/ni.1748 · Cited by 442
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Kaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Antibody-Drug Conjugates for Cancer Therapy
Carter, P. J., & Senter, P. D. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e318172d704 · Cited by 429
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
Antibody Conjugate Therapeutics: Challenges and Potential
Teicher, B. A., & Chari, R. V. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1417 · Cited by 427
Advances in recombinant antibody manufacturing
Kunert, R., & Reinhart, D. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7388-9 · Cited by 417
Mellor, J. D., Brown, M. P., Irving, H. R., Zalcberg, J. R., & Dobrovic, A. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-1 · Cited by 415
Agonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels
Vaccaro, C., Zhou, J., Ober, R. J., & Ward, E. S. (2005) · Nature Biotechnology · doi:10.1038/nbt1143 · Cited by 407
Klein, C., Lammens, A., Schäfer, W., Georges, G., Schwaiger, M., Mössner, E., Hopfner, K.-P., Umaña, P., & Niederfellner, G. (2013) · mAbs · doi:10.4161/mabs.22771 · Cited by 392
Crystal Structure at 2.8 Å of an FcRn/Heterodimeric Fc Complex
Martin, W. L., West, A. P., Gan, L., & Bjorkman, P. J. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00230-1 · Cited by 391
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
Liu, L. (2018) · Protein & Cell · doi:10.1007/s13238-017-0408-4 · Cited by 390
Fcα/μ receptor mediates endocytosis of IgM-coated microbes
Shibuya, A., Sakamoto, N., Shimizu, Y., Shibuya, K., Osawa, M., Hiroyama, T., Eyre, H. J., Sutherland, G. R., Endo, Y., Fujita, T., et al. (2000) · Nature Immunology · doi:10.1038/80886 · Cited by 388
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Structure and function relationships in IgA
Woof, J. M., & Russell, M. W. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.39 · Cited by 367
Robbie, G. J., Criste, R., Dall'Acqua, W. F., Jensen, K., Patel, N. K., Losonsky, G. A., & Griffin, M. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01285-13 · Cited by 366
Zimmerman, E. S., Heibeck, T. H., Gill, A., Li, X., Murray, C. J., Madlansacay, M. R., Tran, C., Uter, N. T., Yin, G., Rivers, P. J., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400490z · Cited by 363
Higel, F., Seidl, A., Sörgel, F., & Friess, W. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.01.005 · Cited by 360
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
Expression of Recombinant Antibodies
Frenzel, A., Hust, M., & Schirrmann, T. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00217 · Cited by 353
In-vitro protein evolution by ribosome display and mRNA display
Lipovsek, D., & Plückthun, A. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.008 · Cited by 353
Strategies for the assessment of protein aggregates in pharmaceutical biotech product development
den Engelsman, J., Garidel, P., Smulders, R., Koll, H., Smith, B., Bassarab, S., Seidl, A., Hainzl, O., & Jiskoot, W. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0297-1 · Cited by 348
Phage display-derived human antibodies in clinical development and therapy
Frenzel, A., Schirrmann, T., & Hust, M. (2016) · mAbs · doi:10.1080/19420862.2016.1212149 · Cited by 346
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Wu, C., Ying, H., Grinnell, C., Bryant, S., Miller, R., Clabbers, A., Bose, S., McCarthy, D., Zhu, R.-R., Santora, L., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1345 · Cited by 344
The impact of glycosylation on monoclonal antibody conformation and stability
Zheng, K., Bantog, C., & Bayer, R. (2011) · mAbs · doi:10.4161/mabs.3.6.17922 · Cited by 342
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Labrijn, A. F., Meesters, J. I., de Goeij, B. E. C. G., van den Bremer, E. T. J., Neijssen, J., van Kampen, M. D., Strumane, K., Verploegen, S., Kundu, A., Gramer, M. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220145110 · Cited by 339
Sampei, Z., Igawa, T., Soeda, T., Okuyama-Nishida, Y., Moriyama, C., Wakabayashi, T., Tanaka, E., Muto, A., Kojima, T., Kitazawa, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057479 · Cited by 336
Secretory IgA N- and O-Glycans Provide a Link between the Innate and Adaptive Immune Systems
Royle, L., Roos, A., Harvey, D. J., Wormald, M. R., Van Gijlswijk-Janssen, D., Redwan, E.-R. M., Wilson, I. A., Daha, M. R., Dwek, R. A., & Rudd, P. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301436200 · Cited by 335
Biophysical Properties of Human Antibody Variable Domains
Ewert, S., Huber, T., Honegger, A., & Plückthun, A. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01237-8 · Cited by 330
Formulation and manufacturability of biologics
Shire, S. J. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.006 · Cited by 330
The Immunoregulatory Roles of Antibody Glycosylation
Jennewein, M. F., & Alter, G. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.02.004 · Cited by 323
Role of J Chain in Secretory Immunoglobulin Formation
Johansen, Braathen, & Brandtzaeg (2000) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2000.00790.x · Cited by 322
A general approach to site-specific antibody drug conjugates
Tian, F., Lu, Y., Manibusan, A., Sellers, A., Tran, H., Sun, Y., Phuong, T., Barnett, R., Hehli, B., Song, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321237111 · Cited by 319
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
Richards, J. O., Karki, S., Lazar, G. A., Chen, H., Dang, W., & Desjarlais, J. R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0201 · Cited by 313
Kwakkenbos, M. J., Diehl, S. A., Yasuda, E., Bakker, A. Q., van Geelen, C. M. M., Lukens, M. V., van Bleek, G. M., Widjojoatmodjo, M. N., Bogers, W. M. J. M., Mei, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2071 · Cited by 300
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
Labrijn, A. F., Buijsse, A. O., van den Bremer, E. T. J., Verwilligen, A. Y. W., Bleeker, W. K., Thorpe, S. J., Killestein, J., Polman, C. H., Aalberse, R. C., Schuurman, J., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1553 · Cited by 298
Xenaki, K. T., Oliveira, S., & van Bergen en Henegouwen, P. M. P. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01287 · Cited by 289
Bispecific antibodies and their applications
Fan, G., Wang, Z., Hao, M., & Li, J. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0227-0 · Cited by 288
Site-Specific PEGylation of Therapeutic Proteins
Dozier, J., & Distefano, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025831 · Cited by 287
Stapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286
Moores, S. L., Chiu, M. L., Bushey, B. S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R. J., Haytko, P., Kelly, T., Wu, S.-J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2833 · Cited by 286
Antibody-Based Immunotherapy of Cancer
Weiner, L. M., Murray, J. C., & Shuptrine, C. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.034 · Cited by 284
Beckman, R. A., Weiner, L. M., & Davis, H. M. (2007) · Cancer · doi:10.1002/cncr.22402 · Cited by 281
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects
Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S. B., Born, T., Retter, M., Manchulenko, K., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.117382 · Cited by 280
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
Vučković, F., Krištić, J., Gudelj, I., Teruel, M., Keser, T., Pezer, M., Pučić‐Baković, M., Štambuk, J., Trbojević‐Akmačić, I., Barrios, C., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39273 · Cited by 269
Moore, G. L., Chen, H., Karki, S., & Lazar, G. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11158 · Cited by 266
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Kovtun, Y. V., Audette, C. A., Mayo, M. F., Jones, G. E., Doherty, H., Maloney, E. K., Erickson, H. K., Sun, X., Wilhelm, S., Ab, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3546 · Cited by 266
Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum
Wuhrer, M., Stam, J. C., van de Geijn, F. E., Koeleman, C. A. M., Verrips, C. T., Dolhain, R. J. E. M., Hokke, C. H., & Deelder, A. M. (2007) · PROTEOMICS · doi:10.1002/pmic.200700289 · Cited by 263
Atwell, S., Ridgway, J. B. B., Wells, J. A., & Carter, P. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1116 · Cited by 261
Applications of single-chain variable fragment antibodies in therapeutics and diagnostics
Weisser, N. E., & Hall, J. C. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.04.004 · Cited by 261
Hood, L., Gray, W. R., Sanders, B. G., & Dreyer, W. J. (1967) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1967.032.01.021 · Cited by 261
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies
Wang, W., Vlasak, J., Li, Y., Pristatsky, P., Fang, Y., Pittman, T., Roman, J., Wang, Y., Prueksaritanont, T., & Ionescu, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2010.12.009 · Cited by 257
Developability Assessment During the Selection of Novel Therapeutic Antibodies
Jarasch, A., Koll, H., Regula, J. T., Bader, M., Papadimitriou, A., & Kettenberger, H. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24430 · Cited by 242
Isotype selection in antibody engineering
Salfeld, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1369 · Cited by 239
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
Applications of Yeast Surface Display for Protein Engineering
Cherf, G. M., & Cochran, J. R. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2748-7_8 · Cited by 237
Subcutaneous Absorption of Biotherapeutics: Knowns and Unknowns
Richter, W. F., & Jacobsen, B. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059238 · Cited by 235
Human immunoglobulin allotypes: Possible implications for immunogenicity
Jefferis, R., & Lefranc, M.-P. (2009) · mAbs · doi:10.4161/mabs.1.4.9122 · Cited by 235
Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcγ receptors
Bertolotti-Ciarlet, A., Wang, W., Lownes, R., Pristatsky, P., Fang, Y., McKelvey, T., Li, Y., Li, Y., Drummond, J., Prueksaritanont, T., et al. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.02.002 · Cited by 235
Eon‐Duval, A., Broly, H., & Gleixner, R. (2012) · Biotechnology Progress · doi:10.1002/btpr.1548 · Cited by 234
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Lewis, S. M., Wu, X., Pustilnik, A., Sereno, A., Huang, F., Rick, H. L., Guntas, G., Leaver-Fay, A., Smith, E. M., Ho, C., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2797 · Cited by 234
Impact of host cell line choice on glycan profile
Goh, J. B., & Ng, S. K. (2018) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1416577 · Cited by 225
Site-Specific Antibody–Drug Conjugation through Glycoengineering
Zhou, Q., Stefano, J. E., Manning, C., Kyazike, J., Chen, B., Gianolio, D. A., Park, A., Busch, M., Bird, J., Zheng, X., et al. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400505q · Cited by 223
Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells
Croset, A., Delafosse, L., Gaudry, J.-P., Arod, C., Glez, L., Losberger, C., Begue, D., Krstanovic, A., Robert, F., Vilbois, F., et al. (2012) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2012.06.038 · Cited by 221
de Jong, R. N., Beurskens, F. J., Verploegen, S., Strumane, K., van Kampen, M. D., Voorhorst, M., Horstman, W., Engelberts, P. J., Oostindie, S. C., Wang, G., et al. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002344 · Cited by 219
Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
Zhao, R. Y., Wilhelm, S. D., Audette, C., Jones, G., Leece, B. A., Lazar, A. C., Goldmacher, V. S., Singh, R., Kovtun, Y., Widdison, W. C., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2002958 · Cited by 215
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Beers, S. A., Chan, C. H. T., French, R. R., Cragg, M. S., & Glennie, M. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.001 · Cited by 209
The human IgM pentamer is a mushroom-shaped molecule with a flexural bias
Czajkowsky, D. M., & Shao, Z. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903805106 · Cited by 206
Fc-Binding Ligands of Immunoglobulin G: An Overview of High Affinity Proteins and Peptides
Choe, W., Durgannavar, T., & Chung, S. (2016) · Materials · doi:10.3390/ma9120994 · Cited by 205
High-Throughput IgG Fc N-Glycosylation Profiling by Mass Spectrometry of Glycopeptides
Baković, M. P., Selman, M. H. J., Hoffmann, M., Rudan, I., Campbell, H., Deelder, A. M., Lauc, G., & Wuhrer, M. (2013) · Journal of Proteome Research · doi:10.1021/pr300887z · Cited by 204
van der Lee, M. M. C., Groothuis, P. G., Ubink, R., van der Vleuten, M. A. J., van Achterberg, T. A., Loosveld, E. M., Damming, D., Jacobs, D. C. H., Rouwette, M., Egging, D. F., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0881-t · Cited by 201
Antibody affinity maturation using bacterial surface display
Daugherty, P. S., Chen, G., Olsen, M. J., Iverson, B. L., & Georgiou, G. (1998) · Protein Engineering Design and Selection · doi:10.1093/protein/11.9.825 · Cited by 199
Johnson, S., Burke, S., Huang, L., Gorlatov, S., Li, H., Wang, W., Zhang, W., Tuaillon, N., Rainey, J., Barat, B., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.04.001 · Cited by 198
Fc fusion as a platform technology: potential for modulating immunogenicity
Levin, D., Golding, B., Strome, S. E., & Sauna, Z. E. (2015) · Trends in Biotechnology · doi:10.1016/j.tibtech.2014.11.001 · Cited by 195
Therapeutic Anti-Cd3 Monoclonal Antibodies: From Bench to Bedside
Kuhn, C., & Weiner, H. L. (2016) · Immunotherapy · doi:10.2217/imt-2016-0049 · Cited by 195
Davis, J. H., Aperlo, C., Li, Y., Kurosawa, E., Lan, Y., Lo, K.-M., & Huston, J. S. (2010) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzp094 · Cited by 194
Lühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S. J., Hanke, T., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021024 · Cited by 193
Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs
Holt, L. J., Basran, A., Jones, K., Chorlton, J., Jespers, L. S., Brewis, N. D., & Tomlinson, I. M. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzm067 · Cited by 193
DeKosky, B. J., Lungu, O. I., Park, D., Johnson, E. L., Charab, W., Chrysostomou, C., Kuroda, D., Ellington, A. D., Ippolito, G. C., Gray, J. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525510113 · Cited by 192
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Natsume, A., In, M., Takamura, H., Nakagawa, T., Shimizu, Y., Kitajima, K., Wakitani, M., Ohta, S., Satoh, M., Shitara, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6297 · Cited by 187
Antibody glycosylation in inflammation, disease and vaccination
Alter, G., Ottenhoff, T. H. M., & Joosten, S. A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.003 · Cited by 186
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
Klein, C., Schaefer, W., & Regula, J. T. (2016) · mAbs · doi:10.1080/19420862.2016.1197457 · Cited by 185
Biophysical Properties of Camelid VHH Domains Compared to Those of Human VH3 Domains
Ewert, S., Cambillau, C., Conrath, K., & Plückthun, A. (2002) · Biochemistry · doi:10.1021/bi011239a · Cited by 184
Turula, H., & Wobus, C. E. (2018) · Viruses · doi:10.3390/v10050237 · Cited by 183
The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity
Bakema, J. E., & van Egmond, M. (2011) · Mucosal Immunology · doi:10.1038/mi.2011.36 · Cited by 182
Rabia, L. A., Desai, A. A., Jhajj, H. S., & Tessier, P. M. (2018) · Biochemical Engineering Journal · doi:10.1016/j.bej.2018.06.003 · Cited by 182
Barthelemy, P. A., Raab, H., Appleton, B. A., Bond, C. J., Wu, P., Wiesmann, C., & Sidhu, S. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708536200 · Cited by 179
The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds
Schuurman, J., Perdok, G. J., Gorter, A. D., & Aalberse, R. C. (2001) · Molecular Immunology · doi:10.1016/s0161-5890(01)00050-5 · Cited by 174
Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry
Akkapeddi, P., Azizi, S., Freedy, A. M., Cal, P. M. S. D., Góis, P. M. P., & Bernardes, G. J. L. (2016) · Chemical Science · doi:10.1039/c6sc00170j · Cited by 174
Antibody Aggregation: Insights from Sequence and Structure
Li, W., Prabakaran, P., Chen, W., Zhu, Z., Feng, Y., & Dimitrov, D. S. (2016) · Antibodies · doi:10.3390/antib5030019 · Cited by 174
White, A. L., Chan, H. T. C., French, R. R., Willoughby, J., Mockridge, C. I., Roghanian, A., Penfold, C. A., Booth, S. G., Dodhy, A., Polak, M. E., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.001 · Cited by 173
Stability of IgG isotypes in serum
Correia, I. (2010) · mAbs · doi:10.4161/mabs.2.3.11788 · Cited by 172
Glycoproteomic Analysis of Antibodies
Zauner, G., Selman, M. H. J., Bondt, A., Rombouts, Y., Blank, D., Deelder, A. M., & Wuhrer, M. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r112.026005 · Cited by 172
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E. M., AlDeghaither, D., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 171
The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer
Stewart, R. A., Hammond, S. A., Oberst, M. D., & Wilkinson, R. W. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0029-x · Cited by 171
Posttranslational Modifications and the Immunogenicity of Biotherapeutics
Jefferis, R. (2016) · Journal of Immunology Research · doi:10.1155/2016/5358272 · Cited by 171
Saxena, A., & Wu, D. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00580 · Cited by 169
In vitro and in vivo modifications of recombinant and human IgG antibodies
Liu, H., Ponniah, G., Zhang, H.-M., Nowak, C., Neill, A., Gonzalez-Lopez, N., Patel, R., Cheng, G., Kita, A. Z., & Andrien, B. (2014) · mAbs · doi:10.4161/mabs.29883 · Cited by 168
Towards the next generation of biomedicines by site-selective conjugation
Hu, Q.-Y., Berti, F., & Adamo, R. (2016) · Chemical Society Reviews · doi:10.1039/c4cs00388h · Cited by 167
Wei, Z., Feng, J., Lin, H.-Y., Mullapudi, S., Bishop, E., Tous, G. I., Casas-Finet, J., Hakki, F., Strouse, R., & Schenerman, M. A. (2007) · Analytical Chemistry · doi:10.1021/ac062311j · Cited by 166
Overview of Antibody Drug Delivery
Awwad, S., & Angkawinitwong, U. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030083 · Cited by 166
Immunogenicity of therapeutic proteins: the use of animal models
Brinks, V., Jiskoot, W., & Schellekens, H. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0523-5 · Cited by 164
[17] Bispecific monoclonal antibodies from hybrid hybridomas
Suresh, M. R., Cuello, A. C., & Milstein, C. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)21019-8 · Cited by 160
Revisiting the Role of Glycosylation in the Structure of Human IgG Fc
Borrok, M. J., Jung, S. T., Kang, T. H., Monzingo, A. F., & Georgiou, G. (2012) · ACS Chemical Biology · doi:10.1021/cb300130k · Cited by 158
Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates
Kalim, M., Chen, J., Wang, S., Lin, C., Ullah, S., Liang, K., Ding, Q., Chen, S., & Zhan, J.-B. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s135571 · Cited by 158
Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Steiner, M., & Neri, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0483 · Cited by 157
Therapeutic monoclonal antibody N-glycosylation – Structure, function and therapeutic potential
Cymer, F., Beck, H., Rohde, A., & Reusch, D. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.11.001 · Cited by 157
Impact of Glycosylation on Effector Functions of Therapeutic IgG
Abès, R., & Teillaud, J. (2010) · Pharmaceuticals · doi:10.3390/ph3010146 · Cited by 156
Improving target cell specificity using a novel monovalent bispecific IgG design
Mazor, Y., Oganesyan, V., Yang, C., Hansen, A. M., Wang, J., Liu, H., Sachsenmeier, K. F., Marcia, C., Gadre, D., Borrok, M. J., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007816 · Cited by 152
Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations
Sharma, S. K., & Bagshawe, K. D. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.009 · Cited by 150
Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Shor, B., Gerber, H., & Sapra, P. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.09.014 · Cited by 149
Antibody–Antibiotic Conjugates: A Novel Therapeutic Platform against Bacterial Infections
Mariathasan, S., & Tan, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.12.008 · Cited by 146
Datta‐Mannan, A., Thangaraju, A., Leung, D., Tang, Y., Witcher, D. R., Lu, J., & Wroblewski, V. J. (2015) · mAbs · doi:10.1080/19420862.2015.1016696 · Cited by 144
Lefranc, M., & Lefranc, G. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-842-9_34 · Cited by 143
Engineering the variable region of therapeutic IgG antibodies
Igawa, T., Tsunoda, H., Kuramochi, T., Sampei, Z., Ishii, S., & Hattori, K. (2011) · mAbs · doi:10.4161/mabs.3.3.15234 · Cited by 143
Generation of Epstein‐Barr Virus (EBV)–Immortalized B Cell Lines
Tosato, G., & Cohen, J. I. (2007) · Current Protocols in Immunology · doi:10.1002/0471142735.im0722s76 · Cited by 142
Affinity maturation of antibodies assisted by in silico modeling
Barderas, R., Desmet, J., Timmerman, P., Meloen, R. H., & Casal, J. I. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801221105 · Cited by 142
Antibody Glycosylation and Inflammation
Shade, K.-T., & Anthony, R. M. (2013) · Antibodies · doi:10.3390/antib2030392 · Cited by 142
Monomeric Fc Fusions: Impact on Pharmacokinetic and Biological Activity of Protein Therapeutics
Dumont, J. A., Low, S. C., Peters, R., & Bitonti, A. J. (2006) · BioDrugs · doi:10.2165/00063030-200620030-00002 · Cited by 139
The era of the immunoglobulin A Fc receptor Fcα RI ; its function and potential as target in disease
Aleyd, E., Heineke, M. H., & van Egmond, M. (2015) · Immunological Reviews · doi:10.1111/imr.12337 · Cited by 137
Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3)
Plomp, R., Dekkers, G., Rombouts, Y., Visser, R., Koeleman, C. A. M., Lageveen‐Kammeijer, G. S. M., Jansen, B. C., Rispens, T., Hensbergen, P. J., Vidarsson, G., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.047381 · Cited by 137
Responsiveness of B cells is regulated by the hinge region of IgD
Übelhart, R., Hug, E., Bach, M. P., Wossning, T., Minden, M. D.-V., Horn, A. H. C., Tsiantoulas, D., Kometani, K., Kurosaki, T., Binder, C. J., et al. (2015) · Nature Immunology · doi:10.1038/ni.3141 · Cited by 136
Naturally occurring glycan forms of human immunoglobulins G1 and G2
Flynn, G. C., Chen, X., Liu, D., Shah, B., & Zhang, Z. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.04.006 · Cited by 135
The Role of FcRn in Antigen Presentation
Baker, K., Räth, T., Pyzik, M., & Blumberg, R. S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00408 · Cited by 132
Ouchida, R., Mori, H., Hase, K., Takatsu, H., Kurosaki, T., Tokuhisa, T., Ohno, H., & Wang, J. O. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210706109 · Cited by 129
Tustian, A. D., Endicott, C. E., Adams, B., Mattila, J., & Bak, H. (2016) · mAbs · doi:10.1080/19420862.2016.1160192 · Cited by 129
Engineering Aggregation-Resistant Antibodies
Perchiacca, J. M., & Tessier, P. M. (2012) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-062011-081052 · Cited by 128
Mazor, Y., Sachsenmeier, K. F., Yang, C., Hansen, A. M., Filderman, J. N., Mulgrew, K. A., Wu, H., & Dall’Acqua, W. F. (2017) · Scientific Reports · doi:10.1038/srep40098 · Cited by 128
Pasut, G. (2014) · BioDrugs · doi:10.1007/s40259-013-0064-z · Cited by 126
Influence of immunoglobulin isotype on therapeutic antibody function
Beers, S. A., Glennie, M. J., & White, A. L. (2016) · Blood · doi:10.1182/blood-2015-09-625343 · Cited by 125
Metabolic Engineering of Monoclonal Antibody Carbohydrates for Antibody–Drug Conjugation
Okeley, N. M., Toki, B. E., Zhang, X., Jeffrey, S. C., Burke, P., Alley, S. C., & Senter, P. D. (2013) · Bioconjugate Chemistry · doi:10.1021/bc4002695 · Cited by 120
Stability engineering of the human antibody repertoire
Rouet, R., Lowe, D., & Christ, D. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.11.029 · Cited by 120
Fischer, N., Elson, G., Magistrelli, G., Dheilly, E., Fouque, N., Laurendon, A., Gueneau, F., Ravn, U., Depoisier, J.-F., Moine, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms7113 · Cited by 120
Arnold, J. N., Radcliffe, C. M., Wormald, M. R., Royle, L., Harvey, D. J., Crispin, M., Dwek, R. A., Sim, R. B., & Rudd, P. M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.11.6831 · Cited by 120
A comparison of biophysical characterization techniques in predicting monoclonal antibody stability
Thiagarajan, G., Semple, A., James, J. K., Cheung, J. K., & Shameem, M. (2016) · mAbs · doi:10.1080/19420862.2016.1189048 · Cited by 120
Cited by
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Candelaria, P. V., Leoh, L. S., Penichet, M. L., & Daniels-Wells, T. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607692 · Cited by 268
Predicting antibody developability profiles through early stage discovery screening
Bailly, M., Mieczkowski, C., Juan, V., Metwally, E., Tomazela, D., Baker, J., Uchida, M., Kofman, E., Raoufi, F., Motlagh, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1743053 · Cited by 228
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Huang, Y., Del Nagro, C. J., Balic, K., Mylott, W. R., Ismaiel, O. A., Ma, E., Faria, M., Wheeler, A. M., Yuan, M., Waldron, M. P., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01187 · Cited by 29
Metadata
- Authors
- Goulet, D. R., & Atkins, W. M.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 109
- Issue
- 1
- Pages
- 74-103
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2948074633
- Cited by
- 302
- References
- 308
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.